Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Viral kinetics of SARS-CoV-2 over the preclinical, clinical, and postclinical period

Sukbin Jang\textsuperscript{a,1}, Ji-Young Rhee\textsuperscript{a,*,1}, Yu Mi\textsuperscript{b}, Bo Kyeung Jung\textsuperscript{c}

\textsuperscript{a} Division of Infectious Diseases, Department of Medicine, Dankook University College of Medicine, Cheonan, Korea
\textsuperscript{b} Division of Infectious Diseases, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
\textsuperscript{c} Department of Laboratory Medicine, Dankook University College of Medicine, Cheonan, Korea

\textbf{A R T I C L E  I N F O}

\textbf{Article history:}
Received 11 June 2020
Received in revised form 27 October 2020
Accepted 28 October 2020

\textbf{Keywords:}
COVID-19
SARS-CoV-2
Viral load

\textbf{A B S T R A C T}

\textbf{Background:} It is necessary to know the viral kinetics and conduct epidemiological investigations of confirmers to prevent the spread of the new infectious disease COVID-19 to the community. To date, no study has been published on viral kinetics during the preclinical and clinical periods of SARS-CoV-2.

\textbf{Methods:} A confirmed case was defined as a patient with positive results by real-time reverse transcription polymerase chain reaction (RT-PCR) assay for SARS-CoV-2. Both specimen types were collected over the whole clinical course in all patients. Asymptomatic patients who had been screened for COVID-19 due to a strong epidemiological link were also enrolled. The study population included 54 hospitalized patients with confirmed COVID-19.

\textbf{Results:} COVID-19 shows a very high viral load on the day of symptom development, which then decreases overall. Rapid viral proliferation was observed 0–5 days before symptoms developed. Cycle threshold (Ct) value was the lowest in the clinical course from 5 days before symptoms to 10 days after symptoms occurred (Ct < 30). The rRT-PCR results were negative approximately 3 weeks after the onset of symptoms. However, there was a continuous pattern that was negative and positive for up to 6 weeks and more.

\textbf{Conclusion:} Considering the characteristic that COVID-19 has a high viral load before symptoms appear, it is necessary to consider to expand the scope of epidemiological investigations. As there is a very low possibility of transmission after 10 days of symptom occurrence, it may be considered to release isolation after 10 days of symptom occurrence in limited resource situations. This study allows for the planning of epidemiological investigations, patient’s ward supply, and follow-up of patients through sequential changes in viral loads over the entire clinical course. In addition, it is possible to estimate the clinical time at which the patient is present.

© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\section{Introduction}

Coronavirus disease-2019 (COVID-19), which started in Wuhan in December 2019, has spread worldwide. As of 20 May 2020, the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (genus Betacoronavirus, family Coronaviridae) has been reported in 227 countries with more than 4,789,205 confirmed cases and 318,789 deaths (World Health Organization, 2020a). Contact screening and extensive testing are proposed methods of blocking the transmission of infectious diseases during pandemics.

It is necessary to know the viral kinetics and conduct epidemiological investigations of confirmers to prevent the spread of COVID-19. To date, there have been no published data on viral loads before and after the onset of symptoms. The purpose of this study was to infer viral kinetics, including preclinical, clinical, and post-clinical periods, to assist in epidemiological investigations, prevent transmission, and predict the patient’s progress.

\section{Methods}

\textbf{Case definition}

A confirmed case was defined as a patient with positive results by rRT-PCR assay for SARS-CoV-2 in upper respiratory specimens.
RNA-dependent was lower transcripts Hilden, fl sized CAGTACGCACACA-3' TAAASACACTATTAGCATA-3' four sequences CATCAGGAGATGC-3' (Forward), 5'-CAR ATGT- TAAASACACTATTAGCATA-3' (Reverse) and 5'-CAGTCGGAACCT- CATCAGGAGATGC-3' (probe in 5-FAM/3'-BHQ format). Primer and probe sequences for the E gene detection were: 5'- ACAGTATGGTCATGTGTGGCGG-3' Primer (Forward), 5'-CAR ATGT TAAASACACTATTAGCATA-3' (Reverse) and 5'-ACACTAGCCATCCT- TACTGCGGTCTG-3' (probe in 5-FAM/3'-BHQ format). A 20 μL reaction contained 5 μL of template RNA, 11 μL of RT-PCR Premix, and 4 μL of each primer/probe mix. Thermal cycling was performed at 50 °C for 30 min for reverse transcription, followed by the inactivation of the reverse transcriptase at 95 °C for 10 min. PCR amplification was performed with 40 cycles of 95 °C for 15 s and 60 °C for 1 min in the CFX-96 real-time PCR detection system (Bio-Rad). Ct values were reported.

Ethics statement

The Institutional Review Board (IRB) at Dankook University Hospital reviewed and approved the study protocol (IRB registration No. 2020-03-029–001); the requirement for written consent was waived.

Results

The study population included 54 hospitalized patients with confirmed COVID-19 (Table 1). The median age of the 54 patients was 45 years (interquartile range, 40–52 years; range, 2–81 years) and 33 (61.1%) were women. Of the 54 patients, 17 (31.5%) had one or more comorbid medical conditions; 41.2% of patients were hypertensive. Eleven cases (20.4%) were asymptomatic when they were confirmed to have COVID-19.

During hospitalization, pneumonia was present in 28 patients (51.8%). Six patients (11.1%) required oxygen supplement therapy: four with nasal cannula, one with facial mask, and one with high flow nasal cannula oxygen therapy. No patients required mechanical ventilator or ECMO therapy. Of 28 patients treated with pneumonia, 1 patient received systemic corticosteroid for the management of acute respiratory distress syndrome.

By May 29, 46 patients were off isolation or discharged. The median day of off-isolation/discharge was 25.0 days after symptom onset (range, 12–49 days).

We evaluated viral kinetics by serial rRT-PCR of respiratory specimens from 54 patients (Figure 1). All patients were sampled regularly by nasopharyngeal swabs, lower respiratory specimens, and within the sputum (Figure 1). RT-PCR results from 6 days before symptoms to 48 days after symptoms were confirmed.

We classified the patient’s test results from the date of symptom occurrence and calculated the average Ct value (Figure 2). The Ct value on the day of symptom development was the lowest at 13.47 (11.85–16.13). The Ct value was lowest in the clinical course from 5 days before symptoms to 10 days after the occurrence of symptoms (Ct < 30).

Out of the twelve people who tested positive for SARS-CoV-2 before symptoms appeared, six people were family members of confirmatory patients and the other six were in close contact with an instructor who was identified as COVID-19-positive in the dance fitness class. The other was a Korean immigrant from the United States and was confirmed by laboratory screening for visits. In one case, a test conducted six days before the symptom occurred showed negative findings (Ct value was 35.82).

In the 36th patient who received systemic corticosteroid, Ct value decreased 10 days after methylprednisolone administration.

| Table 1 | Clinical characteristics of 54 persons with diagnosed coronavirus disease.

| Characteristics | No. (%) |
|------------------|--------|
| Age, y (mean ± standard deviation) | 47.0 ± 13.0 |
| Sex | - |
| M | 21 (38.9) |
| F | 33 (61.1) |
| Preexisting conditions | - |
| Hypertension | 17 (31.5) |
| Diabetes | 6 (11.1) |
| Chronic obstructive pulmonary disease | 1 (1.9) |
| Congestive heart failure | 0 |
| Chronic kidney disease | 2 (3.7) |
| Malignancy | 0 |
| Body mass index, kg/m² (min to max) | 23.6 ± 3.2 |
| Symptoms at admission | - |
| Fever (>37.5 °C) | 17 (31.5) |
| Chills | 9 (16.7) |
| Cough | 21 (38.9) |
| Sputum | 14 (25.9) |
| Dypsnea | 5 (9.3) |
| Rhinorrhea | 9 (16.7) |
| Sore throat | 9 (16.7) |
| Nausea | 1 (1.9) |
| Diarrhea | 4 (7.4) |
| Abdominal pain | 1 (1.9) |
| Myalgia | 14 (25.9) |
| Headache | 5 (9.3) |
| Anosmia or taste abnormality | 4 (7.4) |
| MEWS (Modified Early Warning Score)† | 1.5 ± 0.91 |
| Laboratory findings | - |
| Blood leukocyte count, reference range 4.0–11.0 × 10⁹/L | - |
| <4.0 × 10⁹/L | 9 (16.7) |
| ≥4.0 × 10⁹/L | 45 (83.3) |
| Lymphocyte count, reference range 1.0–3.4 × 10⁹/L | - |
| Lymphopenia, <1.0 × 10⁹/L | 14 (27.2) |
| Platelet count, reference range 182–369 × 10⁹/L | - |
| <150 × 10⁹/L | 7 (13.0) |
| ≥150 × 10⁹/L | 47 (87.0) |
| Hemoglobin, reference range 11.2–15.7 g/dL | - |
| Anemia, <13 g/dL | 13.8 ± 12.3 g/dL |
| C-reactive protein level, >10 mg/L | 12 (22.2) |
| Procalcitonin level >0.5 ng/mL | 1 (1.9) |
| Lactate dehydrogenase >250 IU/L | 24 (44.4) |
| Creatinine >133 μmol/L | 1 (1.9) |
| Alanine aminotransferase >40 IU/L | 7 (13.0) |
| Infiltration in chest x-ray | 28 (51.9) |
| Infiltration in computed tomography | - |
| Supplementary oxygen | 6 (11.1) |

† Characteristics and clinical findings at the time of isolation or hospital admission.

b Mean ± standard deviation.
In the rRT-PCR test performed with the lower respiratory tract specimen, the Ct value decreased from 32.09 to 20.8 (Figure 3).

**Discussion**

COVID-19 shows a very high viral load on the day of symptom development, which then decreases overall. Rapid viral proliferation was observed from 0 to 6 days before the onset of symptoms, suggesting that the risk of transmission is extremely high due to a significant amount of viral load in the early stages of symptoms and preclinical period. A recent study found that a Ct value of 30 or less showed positive findings in viral culture, although viral culture positive Ct does not mean an infectious dose (Arons et al., 2020; Young et al., 2020). In our finding, the Ct value is as low as 30 or less from 5 days before symptom onset to 10 days after symptom onset.

The epidemiological investigation currently being conducted by the WHO (World Health Organization) guideline is set as of the second day before patient symptoms are confirmed (World Health Organization, 2020b). However, our results show it is possible to see a rapid increase in the virus 5 days before symptom occurrence and a very high viral load that can occur 5 days before to 10 days after symptoms occur. Within this Ct range, the virus contains a sufficient amount of virus transmission ability and is sufficient to confirm the contact by more than 3 days before symptoms occur. COVID-19 has a high viral load before symptoms; epidemiological investigations from two days before the symptoms of diagnosed patients according to the WHO guidelines are thought to be difficult to prevent the spread of hidden infections as much as possible. Considering the characteristic that COVID-19 has a high viral load before symptoms appear, it is necessary to consider the expansion of the scope of epidemiological investigations.

In addition, 10 days after symptom onset, the Ct value exceeds 30. As there is a very low possibility of transmission after 10 days of symptom occurrence, it may be considered to release isolation after 10 days of symptom occurrence in limited resource situations.

Based on our findings, even a patient who is currently asymptomatic can deduce the present clinical condition of the patient with the patient’s rRT-PCR results, and the typical COVID-19 patient’s hospitalization can be determined based on the patient’s rRT-PCR results. Recently, a patient was confirmed after returning from the United States and was admitted to the hospital. The patient had no symptoms at that time, but 2 months earlier the patient had severe cold symptoms. At the time of hospitalization, the Ct value of rRT-PCR test performed outside the hospital was as

![Graph showing changes in SARS-CoV-2 Ct value of rRT-PCR in respiratory specimens.](image-url)
Figure 2. Changes in the SARS-CoV-2 Ct value of rRT-PCR in respiratory specimens. The calculated value as the mean of the Ct value of SARS-CoV-2 RNA (RdRP) in the nasopharyngeal specimens. The Ct value shows the lowest value on the day of symptoms and negative 3 weeks from the date of symptoms. (Negative > Ct value 35).

Figure 3. Changes in the SARS-CoV-2 Ct value of rRT-PCR in respiratory specimens of patient 36. A 71-year-old man with a history of diabetes was hospitalized on the 5th day of cough and fever. On the 10th day of symptom onset, dyspnea worsened and tachypnea persisted even after high flow nasal cannula oxygen therapy. On the 10th day of symptom development, methylprednisolone was administered at 0.5 mg/kg for 3 days and then stopped. Oxygen demand was reduced, but it was worsened on the 4th day after discontinuation, so methylprednisolone was taken at 1 mg/kg for 3 days. (The concomitant drugs used during the period of use of methylprednisolone were nafamostat, piperacillin/tazobactam, levofloxacin, and lansoprazole.) After clinical improvement, the prednisolone dose was reduced and finally stopped after 10 days. In the rRT-PCR test after the discontinuation of corticosteroid administration, the Ct value was continuously decreased and negative was confirmed on the 19th day after the final discontinuation.

In addition, it was shown that a high viral load can be maintained for a long time in patients who were administered with corticosteroids in this study. A recent study reported that the use of corticosteroids may delay virus removal and develop bacterial infections caused by immunosuppression (Yang et al., 2020). Therefore, we need to treat this result with caution and selectively apply systemic corticosteroid.

This study is limited by a small sample size (n = 54). In addition, a more comprehensive graph can be created if the results of rRT-PCR from the contact before the onset of symptoms can be added. Further research is needed to determine how much of the viral load is infectious.

In conclusion, changes in viral load allow us to estimate when patients will develop symptoms and determine the scope of epidemiological investigations. This study of viral kinetics provides a basis for estimating the inpatient discharge time and the patient’s isolation release time, which can make the supply and demand of the hospital room predictable.
Disclosure

J-Y Rhee reports grants from 2020 Development Fund of the Dankook University College of Medicine. All other authors have no potential conflicts to disclose.

CRediT authorship contribution statement

Sukbin Jang: Data curation, Formal analysis, Investigation, Writing - original draft, Visualization. Ji-Young Rhee: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing - original draft, Writing - review & editing. Yu Mi Wi: Data curation, Investigation. Bo Kyeung Jung: Data curation, Writing - original draft.

Acknowledgments

This work was supported by the Dankook University College of Medicine. We appreciate the efforts of all the staff and their families at the isolation unit at Dankook University Hospital. We would like to thank all the members of the Cheonansi Government, Seochogu Government, and Korea Centers for Disease Control and Prevention for their dedication.

References

Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med 2020;382(22):2081–90.

Jiang M, Li Y, Han M, Wang Z, Zhang Y, Du X. Recurrent PCR positivity after hospital discharge of people with coronavirus disease 2019 (COVID-19). J Infect 2020;.

World Health Organization. Novel coronavirus (2019-nCoV): situation report—121. Accessed May 21, 2020. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200520-covid-19-sitrep-121.pdf.

World Health Organization. Contact tracing in the context of COVID-19: interim guidance. Accessed May 21, 2020. 2020. https://apps.who.int/iris/rest/bit-streams/1277571/retrieve.

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect 2020;.

Young BE, Ong SWX, Ng LF, Anderson DE, Chia WN, Chia PY, et al. Immunological and Viral Correlates of COVID-19 Disease Severity: A Prospective Cohort Study of the First 100 Patients in Singapore. 2020.